Uncovering Periodic Paralysis

A SPONSORED NO-COST PRIMARY PERIODIC PARALYSIS (PPP) GENETIC TESTING PROGRAM

PPP is a rare and potentially progressive genetic condition.[1-3] Xeris Pharmaceuticals® has partnered with PreventionGenetics to offer a periodic paralysis genetic test for those who have episodic muscle weakness or temporary paralysis provoked by common triggers for PPP.

A genetic test can help shorten the diagnostic journey and expedite clinical management of the disease

ORDER A TEST TODAY

uncoveringperiodicparalysis.com

xeris® PHARMACEUTICALS

PPP is a rare inherited condition[3]

PPP includes several autosomal dominant inherited neuromuscular disorders, which cause **recurrent, progressive, and debilitating episodes of extreme muscle weakness and temporary paralysis**[3,4]

- Although there are other related variants, the most common forms of PPP are hypokalemic periodic paralysis and hyperkalemic periodic paralysis[3,4]

PPP IS OFTEN DIFFICULT TO DIAGNOSE[1,2] AND COMMONLY MISDIAGNOSED[1,2,9]

- Patients in one study reported seeing an average of 4 doctors before receiving a correct diagnosis of PPP[1*]
- Average time from onset of symptoms to correct diagnosis is **26 years**[1†2]
- Patients have reported being misdiagnosed with other conditions, including depression, malingering, conversion disorder, or myotonia congenita[1]

A NEGATIVE TEST DOES NOT RULE OUT A PPP DIAGNOSIS[3]

Patients with a negative test result may still have PPP. Genetic testing can confirm a diagnosis in about 70% of patients, but the remaining 30% don't have one of the commonly identified genetic mutations. These patients can be diagnosed by considering:

- Clinical presentation of symptoms
- History of attacks (as well as serum potassium levels during attacks)
- Response to specific PPP triggers
- Family history
- Ruling out other conditions that mimic PPP
- Other testing such as ECG/EKG, EMG, and CMAP

*Based on a survey of 137 patients ages 19-84 years with a diagnosis of hyperkalemic periodic paralysis who were invited through the internet or one of several healthcare institutions worldwide.

†Based on a survey of 66 self-selected patients over the age of 40 years with a clinical diagnosis of Primary Periodic Paralysis who sought support via the Internet.

ECG/EKG = electrocardiogram; EMG = electromyography; CMAP = compound muscle action potential

Genetic testing is a simple, convenient process

PLACE YOUR ORDER

1. **ORDER ONLINE** Place an order for a specimen collection kit through the ordering portal at **uncoveringperiodicparalysis.com** Your Xeris Area Business Specialist can also provide you with a kit.

2. **COLLECT A SPECIMEN** Make sure to label the sample with the patient's full name, date of birth, and sample collection date.

3. **GET THE RESULTS** Once PreventionGenetics receives the sample, you will receive the results in 18-24 days, on average. If you create an online account, you will be able to track the status of your order and receive a notification email when the test results are ready.

ELIGIBILITY FOR TESTING

- Must be 18+ years of age
- Have a history of episodic muscle weakness, paralysis attacks, or episodic pain after attacks (more than 1 occurrence)
- Have episodes provoked by at least 1 of the common triggers for PPP. Visit **uncoveringperiodicparalysis.com** to view the common triggers of PPP

NO-COST TESTING FOR FAMILY MEMBERS

- Xeris Pharmaceuticals® and PreventionGenetics offer no-cost family variant testing to any blood relative of a patient newly diagnosed through the Uncovering Periodic Paralysis genetic testing program
- Eligibility for family members:
  - » A pathogenic or likely pathogenic variant was found on the original patient's Uncovering Periodic Paralysis gene panel test
- Direct family members do **not** have to meet any of the eligibility requirements (age, triggers, episodes, etc.) to receive family variant testing

xeris® PHARMACEUTICALS

The advantages of the PPP genetic testing panel

- **Screens for hyperkalemic, hypokalemic, and atypical periodic paralyses, as well as Andersen-Tawil syndrome,** including the 6 most commonly associated genes: *ATP1A2*, *SCN4A*, *CACNA1S*, *KCNJ2*, *MCM2AP*, and *RYR1*
- Turnaround time for the panel is rapid. Once PreventionGenetics receives the sample, you will receive the results in 18-24 days, on average
- Board-certified genetic counselors are available to help review patient cases, differentiate between test options, and aid in interpreting results
- If you have questions, you can email **support@preventiongenetics.com**

ORDER A TEST TODAY

A genetic test can help shorten the PPP diagnostic journey and expedite clinical management of the disease
uncoveringperiodicparalysis.com

xeris Care Connection™

ENSURING YOU NEVER WALK ALONE

Providing patients and their providers with expertise in managing critical aspects of the PPP treatment journey

References: 1. Charles G, Zheng C, Lehmann-Horn F, Jurkat-Rott K, Levitt J. Characterization of hyperkalemic periodic paralysis; a survey of genetically diagnosed individuals. *J Neurol.* 2013;260:2606-2613. **2.** Cavel-Greant D, Lehmann-Horn F, Jurkat-Rott K. The impact of permanent muscle weakness on quality of life in periodic paralysis; a survey of 66 patients. Acta Myol. 2012;31:126-133. **3.** Statland JM, Fontaine B, Hanna MG, et al. Review of the diagnosis and treatment of periodic paralysis. *Muscle Nerve.* 2018;57:522-530. **4.** Cannon SC, Channelopathies of skeletal muscle excitability. *Compr Physiol*, 2015;5:761-790. **5.** Hypokalemic Periodic Paralysis. MedlinePlus. Updated March 1, 2020. Accessed November 12, 2024. https://medlineplus.gov/genetics/condition/hypokalemic-periodic-paralysis/. **6.** Hyperkalemic Periodic Paralysis. MedlinePlus. Updated February 1, 2019. Accessed November 12, 2024. https://medlineplus.gov/genetics/condition/hyperkalemic periodic-paralysis/. **7.** Paramyotonia Congenita. MedlinePlus. Updated August 1, 2015. Accessed November 12, 2024. https://medlineplus.gov/genetics/condition/paramyotonia-congenita/. **8.** Andersen-Tawil Syndrome. MedlinePlus. Updated April 1, 2018. Accessed November 12, 2024. Available at: https://medlineplus.gov/genetics/condition/andersen-tawil-syndrome/. **9.** Arya SN. Periodic paralysis. *J Ind Acad Clin Med.* 2002;3:374-382.

1375 West Fulton Street, Suite 1300, Chicago, IL 60607, United States xerispharma.com
Xeris Pharmaceuticals®, Xeris CareConnection™, and their associated logos are trademarks of Xeris Pharmaceuticals, Inc. Copyright © 2024 Xeris Pharmaceuticals, Inc. All rights reserved.
US-KEV-22-00220 V8 12/2024

xeris® PHARMACEUTICALS